来自Ganoderma angustisporum的triterpenoids及其α-葡萄糖酶抑制活性
Fan-Ru Xu1,2, Le Zhou3, Yu-Cheng Dai4
1CAS Key Laboratory of Forest Ecology and Silviculture, Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang, P. R. China.
Natural product research
|March 13, 2026
概括
来自Ganoderma angustisporum的一种新型三类化合物显示出有前途的α-葡萄糖酶抑制. 这种化合物与类似物一起,为开发与α-葡萄糖酶活性相关的疾病的新疗法提供了潜力.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 甘菌 (Ganoderma angustisporum) 是一种以生产生物活性化合物而闻名的真菌.
- 阿尔法-葡萄糖酶抑制剂对于管理2型糖尿病至关重要.
研究的目的:
- 为了隔离和表征来自Ganoderma angustisporum的新型化合物.
- 为了评估分离的化合物的α-葡萄糖酶抑制活性.
主要方法:
- 固体基板培养的Ganoderma angustisporum. 在一个.
- 使用1D/2D NMR和HRESIMS进行结构阐明.
- 在体外α-葡萄糖酶抑制试验和分子对接.
主要成果:
- 一种新的三类化合物 (化合物1) 和八种已知的类似物被分离出来.
- 化合物2表现出强烈的α-葡萄糖酶抑制 (IC50 = 18.26 μM),与阿卡尔相似.
- 分子对接揭示了化合物2通过键与α-葡萄糖酶活性部位的结合.
结论:
- 甘菌 (Ganoderma angustisporum) 是一种强大的α-葡萄糖酶抑制剂的来源.
- 化合物2显示了与α-葡萄糖酶相关疾病的治疗潜力.
- 对化合物2的机制和有效性的进一步研究是有必要的.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
746
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
746
Dipeptidyl Peptidase 4 Inhibitors
860
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860
Enzyme Inhibition
94.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
94.5K
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.9K


